Kelly Dominic, Imft Llc | |
10955 Clearport Rd Sw Amanda OH 43102-9612 | |
(330) 730-9511 | |
Not Available |
Full Name | Kelly Dominic, Imft Llc |
---|---|
Speciality | Community/behavioral Health |
Location | 10955 Clearport Rd Sw, Amanda, Ohio |
Authorized Official Name and Position | Kelly M Dominic (MARRIAGE AND FAMILY THERAPIST OWNER) |
Authorized Official Contact | 3307309511 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Kelly Dominic, Imft Llc 10955 Clearport Rd Sw Amanda OH 43102-9612 Ph: (330) 730-9511 | Kelly Dominic, Imft Llc 10955 Clearport Rd Sw Amanda OH 43102-9612 Ph: (330) 730-9511 |
NPI Number | 1811698657 |
---|---|
Provider Enumeration Date | 03/16/2023 |
Last Update Date | 03/16/2023 |
Certification Date | 03/16/2023 |
Identifier | Type | State | Issuer |
---|---|---|---|
1811698657 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
251S00000X | Community/behavioral Health | (* (Not Available)) | Primary |
News Archive
Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.
Northstar Healthcare Inc. today announced that it received an advance in the amount of Cdn.$1,016,150 from Canada Healthcare Acquisition Inc., a corporation indirectly controlled by Dr. Donald L. Kramer, M.D., a former CEO and former director of Northstar.
A Massachusetts General Hospital research team has reported that repeated treatment with pulsed electric fields - a noninvasive procedure that does not generate heat - may help reduce the development of scarring.
In response to a recent Wall Street Journal op-ed by Whole Foods' Chief Executive Officer John Mackey, activists, consumers and labor groups around the country have been organizing in opposition to his efforts to undermine meaningful health care reform.
Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of KetotransdelĀ® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.
› Verified 8 days ago